Structural characterization of an activin class ternary receptor complex reveals a third paradigm for receptor specificity.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
30 07 2019
Historique:
pubmed: 19 7 2019
medline: 31 3 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

TGFβ family ligands, which include the TGFβs, BMPs, and activins, signal by forming a ternary complex with type I and type II receptors. For TGFβs and BMPs, structures of ternary complexes have revealed differences in receptor assembly. However, structural information for how activins assemble a ternary receptor complex is lacking. We report the structure of an activin class member, GDF11, in complex with the type II receptor ActRIIB and the type I receptor Alk5. The structure reveals that receptor positioning is similar to the BMP class, with no interreceptor contacts; however, the type I receptor interactions are shifted toward the ligand fingertips and away from the dimer interface. Mutational analysis shows that ligand type I specificity is derived from differences in the fingertips of the ligands that interact with an extended loop specific to Alk4 and Alk5. The study also reveals differences for how TGFβ and GDF11 bind to the same type I receptor, Alk5. For GDF11, additional contacts at the fingertip region substitute for the interreceptor interactions that are seen for TGFβ, indicating that Alk5 binding to GDF11 is more dependent on direct contacts. In support, we show that a single residue of Alk5 (Phe

Identifiants

pubmed: 31315975
pii: 1906253116
doi: 10.1073/pnas.1906253116
pmc: PMC6681762
doi:

Substances chimiques

Bone Morphogenetic Proteins 0
Multiprotein Complexes 0
Receptors, Transforming Growth Factor beta 0
Transforming Growth Factor beta 0
Activins 104625-48-1

Banques de données

PDB
['6MAC']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15505-15513

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM058670
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM127726
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008307
Pays : United States

Déclaration de conflit d'intérêts

Conflict of interest statement: T.B.T. is a consultant for Acceleron Pharma and Scientific Founder for Eclode. R.C. and R.K. are current employees of Acceleron Pharma with ownership interest in the company. A.N.E. and V.J.I. are current employees of Regeneron Pharmaceuticals with ownership interest in the company. The other authors report no competing interests.

Références

Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9306-11
pubmed: 11459935
Biol Chem. 2001 Aug;382(8):1189-95
pubmed: 11592400
Mol Pharmacol. 2002 Jul;62(1):65-74
pubmed: 12065756
Genes Dev. 2002 Nov 1;16(21):2749-54
pubmed: 12414726
EMBO J. 2003 Apr 1;22(7):1555-66
pubmed: 12660162
Mol Cell. 2003 Mar;11(3):605-17
pubmed: 12667445
Mol Cell Biol. 2003 Oct;23(20):7230-42
pubmed: 14517293
Nat Struct Mol Biol. 2004 May;11(5):481-8
pubmed: 15064755
Mol Cell. 2004 Aug 13;15(3):485-9
pubmed: 15304227
Protein Expr Purif. 2004 Oct;37(2):265-72
pubmed: 15358346
Annu Rev Cell Dev Biol. 2004;20:61-86
pubmed: 15473835
J Mol Biol. 2005 Jun 24;349(5):933-47
pubmed: 15890363
J Clin Invest. 2005 Sep;115(9):2373-81
pubmed: 16127465
J Mol Biol. 2005 Dec 16;354(5):1052-68
pubmed: 16289576
EMBO J. 2006 Mar 8;25(5):1035-45
pubmed: 16482217
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7643-8
pubmed: 16672363
EMBO Rep. 2006 Aug;7(8):831-7
pubmed: 16845371
BMC Struct Biol. 2007 Feb 12;7:6
pubmed: 17295905
Endocr J. 2008 Mar;55(1):11-21
pubmed: 17878607
Mol Cell. 2008 Feb 1;29(2):157-68
pubmed: 18243111
J Biol Chem. 2008 Nov 21;283(47):32831-8
pubmed: 18768470
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
EMBO J. 2009 Sep 2;28(17):2662-76
pubmed: 19644449
BMC Biol. 2009 Sep 07;7:59
pubmed: 19735544
J Biol Chem. 2010 May 7;285(19):14806-14
pubmed: 20207738
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Biol Chem. 2010 Jul 2;285(27):21037-48
pubmed: 20385559
Science. 2010 Jul 2;329(5987):52-6
pubmed: 20488990
EMBO J. 2011 Apr 6;30(7):1263-76
pubmed: 21423151
J Mol Biol. 2011 Sep 30;412(4):601-18
pubmed: 21821041
J Biol Chem. 2012 Jan 6;287(2):1043-53
pubmed: 22052913
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
FEBS Lett. 2012 Jul 4;586(14):1860-70
pubmed: 22651914
J Biol Chem. 2012 Aug 10;287(33):27313-25
pubmed: 22718755
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Wiley Interdiscip Rev Dev Biol. 2013 Jan-Feb;2(1):47-63
pubmed: 23799630
Nat Med. 2014 Apr;20(4):398-407
pubmed: 24658077
J Bone Miner Res. 2014 Sep;29(9):1950-9
pubmed: 24692083
IUCrJ. 2014 May 30;1(Pt 4):213-20
pubmed: 25075342
Nucleic Acids Res. 2015 Jul 1;43(W1):W314-9
pubmed: 25908787
Cell Commun Signal. 2015 Jun 06;13:27
pubmed: 26047946
BMC Biol. 2015 Sep 18;13:77
pubmed: 26385096
Cytokine Growth Factor Rev. 2016 Feb;27:13-34
pubmed: 26690041
Acta Crystallogr F Struct Biol Commun. 2016 Mar;72(Pt 3):160-4
pubmed: 26919518
J Biol Chem. 2016 May 13;291(20):10792-804
pubmed: 26961869
Nat Commun. 2016 Jul 04;7:12052
pubmed: 27373274
Cold Spring Harb Perspect Biol. 2016 Dec 1;8(12):null
pubmed: 27638177
BMC Biol. 2017 Mar 3;15(1):19
pubmed: 28257634
J Biol Chem. 2017 Aug 18;292(33):13809-13822
pubmed: 28659341
EMBO J. 2018 Feb 1;37(3):367-383
pubmed: 29330193
Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):E866-E875
pubmed: 29348202
Acta Crystallogr D Struct Biol. 2018 Jun 1;74(Pt 6):506-518
pubmed: 29872002
Nature. 1994 Aug 4;370(6488):341-7
pubmed: 8047140
Cell. 1993 Nov 19;75(4):671-80
pubmed: 8242742

Auteurs

Erich J Goebel (EJ)

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, OH 45267.

Richard A Corpina (RA)

Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, NY 10591.

Cynthia S Hinck (CS)

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260.

Magdalena Czepnik (M)

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, OH 45267.

Roselyne Castonguay (R)

Discovery Group, Acceleron Pharma, Cambridge, MA 02139.

Rosa Grenha (R)

Discovery Group, Acceleron Pharma, Cambridge, MA 02139.

Angela Boisvert (A)

Discovery Group, Acceleron Pharma, Cambridge, MA 02139.

Gabriella Miklossy (G)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030.

Paul T Fullerton (PT)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030.

Martin M Matzuk (MM)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030.

Vincent J Idone (VJ)

Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, NY 10591.

Aris N Economides (AN)

Skeletal Diseases Therapeutic Focus Area, Regeneron Pharmaceuticals, Tarrytown, NY 10591.

Ravindra Kumar (R)

Discovery Group, Acceleron Pharma, Cambridge, MA 02139.

Andrew P Hinck (AP)

Department of Structural Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260.

Thomas B Thompson (TB)

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati, Cincinnati, OH 45267; tom.thompson@uc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH